Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metastases to adrenals05.01.04.007; 16.22.02.0120.000280%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.001500%Not Available
Metastases to kidney16.22.02.017; 20.01.04.0100.000224%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000582%Not Available
Metastases to pleura22.05.04.002; 16.22.02.0220.000168%Not Available
Metastases to skin23.07.04.026; 16.22.02.0230.000168%Not Available
Metastases to the mediastinum22.09.03.009; 16.22.02.0270.000112%Not Available
Pneumothorax spontaneous22.05.02.0070.000224%Not Available
Recurrent cancer16.16.01.0150.000414%Not Available
Renal cancer recurrent20.01.04.013; 16.08.02.0070.000336%Not Available
Renal cancer stage IV20.01.04.014; 16.08.02.0080.000112%Not Available
Renal cell carcinoma stage IV20.01.04.016; 16.08.02.0100.000280%Not Available
Renal haematoma24.07.07.004; 20.01.02.018; 12.01.05.0060.000112%Not Available
Retroperitoneal cancer07.21.03.008; 16.13.04.0060.000112%Not Available
Synovial sarcoma16.33.01.004; 15.09.03.0220.000448%Not Available
Urinary bladder haemorrhage24.07.01.086; 20.03.01.0230.000302%Not Available
Uterine leiomyosarcoma21.07.02.013; 16.33.07.0030.000224%Not Available
Concomitant disease progression08.01.03.0640.000112%Not Available
Terminal state08.01.03.0790.000280%Not Available
Neck mass15.03.02.0070.000437%Not Available
Metastases to pancreas07.21.09.005; 16.22.02.0200.000336%Not Available
Renal cancer metastatic20.01.04.012; 16.08.02.0060.001567%Not Available
Small intestinal haemorrhage24.07.02.019; 07.12.03.0020.000112%
Lymphangiosis carcinomatosa24.09.02.007; 16.22.02.009; 01.09.01.0270.000168%Not Available
Adrenal mass05.01.03.0030.000112%Not Available
Cardiac ventricular thrombosis02.11.01.008; 24.01.05.0060.000168%Not Available
Dermatofibrosarcoma protuberans16.33.03.002; 15.09.03.0140.000112%Not Available
Cell death14.11.02.005; 08.03.03.0030.000392%Not Available
Gastrointestinal oedema07.11.01.0120.000224%Not Available
Postrenal failure20.01.03.0210.000112%Not Available
The 19th Page    First    Pre   19 20 21    Next   Last    Total 21 Pages